Replimune: Stock Buoyant On Third Try At RP1 Approval - FDA AdCom May Be Crucial

Replimune Group, Inc. nears a pivotal FDA AdCom for RP1 ahead of an Aug 2, 2026 decision. Click for this REPLY stock update ...